Navigation Links
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/30/2009

SEATTLE, WA, May 30 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida. The presentations included long-term safety data from the Phase 2b trial of Stimuvax(R) in patients with stage IIIB/IV non-small cell lung cancer, preliminary results from the Phase 1 trial of the phosphoinositide-3-kinase (PI-3 kinase) inhibitor PX-866 in patients with advanced malignancy, and final results from two Phase 1b trials of the thioredoxin inhibitor PX-12 in advanced cancer patients.

Stimuvax

Data concerning the long-term safety of Stimuvax (BLP25 liposomal vaccine) were presented by Dr. Charles Butts, Cross Cancer Institute, Edmonton, Alberta. Sixteen patients who received Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) were studied. Ten of these patients have been treated for more than five years, and eight continue to receive therapy with Stimuvax. Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

"We are very pleased that this group of long-term survivors with advanced NSCLC has been able to continue to receive Stimuvax with apparent safety for up to eight years," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "These patients were treated as part of the randomized Phase 2b trial conducted by Oncothyreon, in which the subset of patients with Stage IIIb locoregi
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company ... Therabron Therapeutics , Inc. The new name is derived ... structure in the lungs similar to branches on a ... protein therapeutics for the treatment of respiratory diseases. ... name to mark the company's escalation into the clinical ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna ... company focused on,endocrine therapy and oncology, will announce ... live webcast presentation and conference call hosted by,President ... the outcome,of management,s review of the Company,s pipeline ...
... /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) announced today that Gregory M.,McKee, the ... conferences: BioContact Quebec 2007 (Quebec, Canada): ... Mr. McKee is scheduled to present on Thursday, October 4th at ... Salle Laval Room at the Fairmont Le ...
... Pa., Oct. 2 Monitorforhire.com, the,fastest source ... its,service even faster. The company has added ... and respond immediately to work requests via,PDA ... Scott Freedman, president of monitorforhire.com says ...
Cached Biology Technology:AEterna Zentaris Announces Outcome of Management's Strategic Review 2AEterna Zentaris Announces Outcome of Management's Strategic Review 3AEterna Zentaris Announces Outcome of Management's Strategic Review 4Nventa's CEO to present at two upcoming investor conferences 2
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... and 19th centuries led waves of daring expeditions into ... and fauna and people. , But they were more ... the author of a new book. These seafaring naturalists ... network of scientific knowledge," argues historian Harry Liebersohn, the ...
... creating a topiary garden. Shrubs don't automatically assume the ... cells immediately recognize the "right" target cell. Abundant foliage, ... be sculpted into an ordered structure. , Neurons extend ... manner--some branch to the "wrong" cells while others shoot ...
... and often-deadly mystery disease now called SARS emerged explosively ... 916 people in Asia, Europe, and North and South ... , When scientists identified the virus that caused ... a coronavirus--a virus family whose other members cause many ...
Cached Biology News:Polynesia explorers created worldwide web of scientific knowledge 2Polynesia explorers created worldwide web of scientific knowledge 3Polynesia explorers created worldwide web of scientific knowledge 4Salk and Stanford teams join forces to reveal two paths of neurodegeneration 2Salk and Stanford teams join forces to reveal two paths of neurodegeneration 3Researchers find 'secret weapon' used by SARS virus 2
... Storage Racks for Standard 3" Boxes. ... all makes and models of upright ... high quality stainless steel and can ... steel or plastic boxes. Custom ...
... assays utilize the membrane-permeant ester forms ... charged fluorescent beta-lactamase substrates, CCF2 and ... the cell, where cleavage by endogeneous ... their negatively charged forms, thereby trapping ...
... The ISOQUANT(R) Isoaspartate Detection Kit is ... residues in proteins and peptides, which can ... asparagine or rearrangement of aspartic acid residues ... does not depend on the monitoring of ...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Biology Products: